Phase 3
A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
Gilead said that the Phase III trial for mild to moderate patients had been ended because of lack of patients to enroll.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 15, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
A preliminary analysis of late-stage trial data shows that BeiGene’s investigational checkpoint inhibitor tislelizumab is hitting the mark as a potential first-line treatment in patients with non-squamous non-small cell lung cancer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.
It was a very busy week for clinical trial news. Here’s a look.
As COVID-19 has swept across the world, companies have had to make significant adjustments to the way business is conducted in a global economy. It has impacted all types of operations, including clinical trials.
PRESS RELEASES